Lori Leskin Speaks with The New York Times on New FDA Guidance for Social Media Use by Drug Companies
As Seen in The New York Times’ “FDA Proposes Rules for Listing Risks on Social Media”
The New York Times reports that the FDA issued a set of proposed rules on Tuesday that would require pharmaceutical and medical device companies to list the risks of their products in Twitter feeds if benefits are also mentioned. The rules would to other social media platforms that similarly limit message length. The guidelines also allow these industries to fix any information posted by third parties that could be seen as false or misleading.
According to Kaye Scholer Life Sciences Partner Lori Leskin, companies have hesitated to use Facebook and Twitter in the past due to uncertainty in the FDA rules and for fear of censure.
Also of Interest
- What’s Really Remarkable about the Appeals Court Ruling on the CFPB October 20, 2016 • Articles
- Winning the War: Strategies for Prevailing in Consumer Fraud and False Advertising... October 17, 2016 • Articles
- Kaye Scholer Clients Achieve Nearly Full Recovery in Arch Coal Chapter 11 Proceeding October 14, 2016 • Client Successes
- 3D Printing: New Legal Issues Emerge with the Technology’s Revolutionary Potential October 10, 2016 • Articles
- Consumer Products in the Age of Big Data October 4, 2016 • Articles
- Antitrust Jurisprudence in the Second Circuit October 1, 2016 • Articles
- And Now A Word From The Panel: 3 Alternatives To MDLs September 28, 2016 • Articles
- Kaye Scholer Represents Investors in Volkswagen Diesel Emissions Litigation September 28, 2016 • Client Successes
- NLJ Names Shores as Antitrust Trailblazer September 27, 2016 • Recognitions